Table 1. Patient Characteristics at the Time of Initial Stereotactic Radiosurgery (SRS).
n: number; IQR: interquartile range; F: female; M: male; KPS: Karnofsky performance status; cc: cubic centimeters
| Overall | |
| n | 107 |
| Age (median {IQR}) | 63.00 {53.00-72.25} |
| Sex (%) | |
| F | 31 (29.0) |
| M | 76 (71.0) |
| BRAF status (%) | |
| Wildtype | 21 (19.6) |
| Mutated | 20 (18.7) |
| Unknown | 66 (61.7) |
| Extent of extracranial disease (%) | |
| None | 32 (29.9) |
| Oligometastatic (≤ 5 extracranial mets) | 56 (52.3) |
| Widespread (> 5 extracranial mets) | 15 (14.0) |
| Unknown | 4 (3.7) |
| Prior systemic therapy (%) | |
| Any targeted agent | 41 (38.3) |
| Ipilimumab | 33 (30.8) |
| Vemurafenib | 10 (9.3) |
| Dabrafenib | 8 (7.5) |
| Trametinib | 7 (6.5) |
| Pembrolizumab | 5 (4.7) |
| KPS (%) | |
| 60 | 8 (7.5) |
| 70 | 18 (16.8) |
| 80 | 50 (46.7) |
| 90 | 28 (26.2) |
| 100 | 3 (2.8) |
| Initial number of brain metastases (%) | |
| 1 | 47 (43.9) |
| 2 | 23 (21.5) |
| 3 | 17 (15.9) |
| 4 | 8 (7.5) |
| 5 | 2 (1.9) |
| ≥ 6 | 10 (9.4) |
| Total volume of all brain metastases at initial SRS, cc (median {IQR}) | 2.81 {0.84-7.79} |